Latest Payments News

Key Petroleum Limited progresses Potential Commercial Area applications for ATPs 920 and 924 in Queensland’s Cooper Eromanga Basin, supported by a recent capital raise despite a constrained cash balance.

Oneview Healthcare reported a robust Q4 2024 cash flow update, bolstered by a significant equity raise and expanding partnerships, positioning the company for accelerated growth in 2025.

Pengana Global Private Credit Trust has announced an ordinary unfranked dividend of AUD 0.0116 per unit, payable in mid-February 2025, reflecting steady income distribution for investors.

ENRG Elements Limited reported a $586,000 net cash outflow for the December quarter, offset by a $2.02 million equity raise, boosting its cash reserves to $2.52 million.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

8VI Holdings Limited has confirmed its voluntary delisting from the ASX, reporting a challenging quarter marked by declining cash reserves and a strategic pivot towards preventive care that is yet to yield significant revenue.

Kalamazoo Resources Limited reported a $449,000 net cash outflow from operating activities in Q2 2024, maintaining a cautious stance as it explores funding options to sustain its exploration efforts.

Bod Science Limited reports a modest net cash inflow of $51,000 for Q2 FY2025, supported by increased customer receipts and intellectual property sales, while navigating a complex Deed of Company Arrangement and pending acquisition.

360 Capital Group has announced a fully franked dividend of AUD 0.02 per security for the six months ending December 31, 2024, payable on January 24, 2025. This update confirms the payment details and clarifies the distribution source.

Ten Sixty Four Limited has received a crucial US$10.5 million payment from Philsaga Mining Corporation, enabling it to settle outstanding related party debts and advance its Deed of Company Arrangement.

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.

Midway Limited has announced a special dividend of AUD 0.3835 per share, contingent on key approvals tied to its proposed acquisition by RCM BidCo Pty Ltd.